Chronic Lymphoblastic Lymphoma – Pipeline Review, H2 2012

Chronic Lymphoblastic Lymphoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012', provides an overview of the Chronic Lymphoblastic Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphoblastic Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Lymphoblastic Lymphoma. 'Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Lymphoblastic Lymphoma.
- A review of the Chronic Lymphoblastic Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Lymphoblastic Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Lymphoblastic Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Lymphoblastic Lymphoma pipeline depth and focus of Chronic Lymphoblastic Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Lymphoblastic Lymphoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Chronic Lymphoblastic Lymphoma 7
Chronic Lymphoblastic Lymphoma Therapeutics under Development by Companies 9
Chronic Lymphoblastic Lymphoma Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Chronic Lymphoblastic Lymphoma Therapeutics – Products under Development by Companies 13
Chronic Lymphoblastic Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Chronic Lymphoblastic Lymphoma Therapeutics Development 15
Bristol-Myers Squibb Company 15
Chronic Lymphoblastic Lymphoma – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
Therapeutic Allogeneic Lymphocytes - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Hyper-CVAD + Filgrastim + Nelarabine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 24
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 27
Rituximab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Clofarabine + Etoposide + Asparaginase + Mitoxantrone + Dexamethasone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
BMS-906024 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Chronic Lymphoblastic Lymphoma Therapeutics - Dormant Products 32
Chronic Lymphoblastic Lymphoma – Product Development Milestones 33
Featured News & Press Releases 33
Dec 13, 2011: Immunomedics Announces Results From Phase II Trial Of Epratuzumab At Hematology Conference 33
Dec 11, 2011: Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma 33
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products Under Development for Chronic Lymphoblastic Lymphoma, H2 2012 7
Products under Development for Chronic Lymphoblastic Lymphoma – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Bristol-Myers Squibb Company, H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Chronic Lymphoblastic Lymphoma Therapeutics – Dormant Products 32

List of Figures
Number of Products under Development for Chronic Lymphoblastic Lymphoma, H2 2012 7
Products under Development for Chronic Lymphoblastic Lymphoma – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21